Biocryst Pharmaceuticals, Inc.

Birmingham, AL 35244

Market Performance

NASDAQ: BCRX
Market Cap $362 Million
52 Week High $9.25
52 Week Low $3.75

SBIR Award Summary

Total Number of Awards 8
Total Value of Awards $698K
First Award Date 09/01/91
Most Recent Award Date 07/01/04

Key Personnel

Last Name Name Awards Contact
Babu Y Sudhakara Babu 6
Borhani David W Borhani 1
Arnold Christopher S Arnold 1

8 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-00-126
Budget: 07/01/04 - 06/30/06

DESCRIPTION (provided by applicant): The over-all objective of this project is identifying and developing selective nontoxic inhibitors of the hepatitis C virus NS5B polymerase and eventually testing them as therapeutics for chronic hepatitis C. At least four million people in the United States have chronic hepatitis C and the recent NIH Consen...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/20/04 - 04/20/05

DESCRIPTION (provided by applicant): This program is focused on the development of a small-molecule tissue factor/factor Vlla (TF/FVIla) inhibitor with unique anti-inflammatory properties as a novel therapeutic agent for the treatment of unstable angina. The aims involve testing the effects of BCX-3607, the TF/FVIla inhibitor, in diverse animal ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-00-126
Budget: 07/05/03 - 06/30/04

DESCRIPTION (provided by applicant): The over-all objective of this project is identifying and developing selective nontoxic inhibitors of the hepatitis C virus NS5B polymerase and eventually testing them as therapeutics for chronic hepatitis C. At least four million people in the United States have chronic hepatitis C and the recent NIH Consen...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/05/95 - 02/15/96

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/16/94 - 02/15/95

Complement protein Factor D plays an important role in the alternative pathway of the complement system. Inhibitors for Factor D have potential application in treatment of adult respiratory syndrome (ARDS) and autoimmune diseases such as rheumatoid arthritis. The phase I aim of this proposal was to determine three-dimensional structure of Facto...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/92 - 03/31/93

The long-term objective of this proposal is to design and develop potent and highly specific inhibitors of the enzyme aldose reductase. Aldose reductase catalyzes the reduction of glucose to sorbitol. It has been implicated in the pathogenesis of the chronic complications of diabetes mellitus. Current inhibitors of this enzyme lack specificit...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/10/92 - 08/09/92

DESCRIPTION: (Adapted from the Applicants Abstract). Complement protein Factor D plays an important role in the alternative pathway of the complement system. Inhibitors for Factor D have potential application in the treatment of adult respiratory syndrome (ARDS) and autoimmune diseases such as rheumatoid arthritis. The Phase I aim of this pr...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/91 - 02/29/92

DESCRIPTION: (Adapted from Applicant's Abstract) Influenza is a serious disease that causes about 10,000 to 20,000 deaths in an average season. Even though vaccines have been available for a number of years , they poorly control influenza in the human population. The lack of effectiveness of the vaccine therapy is due to the capacity of the vi...